NCT01183910Unknown不适用
A Randomized, Double-Blind, Placebo-Controlled Study To Assess the Safety and Efficacy of a Novel Oral Natural Extract for the Treatment of Senile Purpura
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 75
- 试验地点
- 2
- 主要终点
- IMPROVEMENT IN PATIENT'S SKIN APPEARANCE WITH SENILE PURPURA
研究概览
简要总结
A randomized, double-blind, placebo controlled study to assess the safety and effectiveness of a novel oral natural extract to improve the appearance of the skin of patients with senile purpura.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Patients with evidence of purpura on physical exam
排除标准
- •Preexisting condition that would not allow the patients to take oral calcium supplement
结局指标
主要结局
IMPROVEMENT IN PATIENT'S SKIN APPEARANCE WITH SENILE PURPURA
时间窗: 6 WEEKS
次要结局
- ADVERSE EFFECTS IN PATIENTS WITH SENILE PURPURA TAKING THIS MEDICATION(6 WEEKS)
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
2 期
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary FibrosisPulmonary Fibrosis Secondary to Systemic SclerosisPulmonary Fibrosis, Interstitial Lung DiseaseInterstitial Lung Disease Due to Connective Tissue Disease (Disorder)Interstitial Lung Disease in Patients With Rheumatoid ArthritisInterstitial Lung Disease With Progressive Fibrotic Phenotype in Diseases Classified ElsewhereInterstitial Lung Disease With Systemic SclerosisPulmonary FibrosisHypersensitivity PneumonitisInterstitial Lung DiseaseNCT06329401Avalyn Pharma Inc.375
已完成
不适用
A Clinical Trial to Evaluate the Efficacy and Safety of MXP22 on Liver HealthNon-Alcoholic Fatty Liver DiseaseNCT05808049Vedic Lifesciences Pvt. Ltd.60
已完成
3 期
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's DiseaseCrohn's DiseaseNCT01277666GlaxoSmithKline608
进行中（未招募）
2 期
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA VaccineCOVID-19NCT05636319Suzhou Abogen Biosciences Co., Ltd.14,168
已完成
2 期
Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract InfectionsAcute PyelonephritisComplicated Urinary Tract InfectionNCT03445195Entasis Therapeutics80